MedaSystems Featured at the Society for Neuro-Oncology (SNO) Annual Meeting
MedaSystems Recognized in Research at the SNO Meeting
MedaSystems will be spotlighted in not one, but two research posters, showcasing our cutting-edge software solutions for Expanded Access programs. We will be presented at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting in Houston, TX, from November 21–24, 2024.
This recognition highlights our team's dedication to innovation and improving patient lives. The research posters illustrate how MedaSystems' next-gen platform transforms Expanded Access programs, enabling research teams to streamline operations and accelerate access to vital therapies for patients with urgent medical needs.
đź“„ Explore the Posters:
VAL-083 in patients with recurrent glioblastoma treated under expanded access program
Highlights the critical role of Expanded Access programs in providing treatment options for recurrent glioblastoma patients.
Presented by Carlos Kamiya-Matsuoka, MD Anderson Cancer Center, British Columbia Cancer-Vancouver Centre, and Valent Technologies.
RELA fusion-positive ependymoma, diffuse midline glioma, and Grade 4 IDH mutant astrocytoma treated under expanded access: case reports
Explores real-world insights into Expanded Access for patients with rare, aggressive tumors.
Presented by Carlos Kamiya-Matsuoka, MD Anderson Cancer Center, and Valent Technologies.
These studies underscore MedaSystems' vital role as a leading software solution provider:
Enhancing Efficiency: We streamline Expanded Access programs, enabling life sciences organizations to operate at peak efficiency.
Ensuring Success: Our platform simplifies data collection and regulatory compliance, paving the way for successful program execution and the advancement of innovative treatments.
As a trusted ally to pharmaceutical companies, MedaSystems is dedicated to empowering research teams with intuitive software tools that transform Expanded Access programs into seamless, scalable, and compliant operations.
Curious about how MedaSystems can elevate your Expanded Access or Post-Trial Access programs? Let’s connect and explore the possibilities together!